|
|
 |
|
Viewing report
|
|
|
|
Neuropathic Pain: Emerging Drugs and Current Treatment Practices
BioPharm Reports (VennBio Ltd.), Feb 2010, Pages: 166
This report presents a comprehensive update on emerging drug candidates for neuropathic pain, (NP) together with the findings of global survey on current treatment practices in the clinic, following the participation of more than 350 physicians worldwide. The global prevalence of NP is unknown; however, recent studies suggest levels of 3-10%. In a 2009 study by Biopharm Reports involving more than 350 physicians, NP was linked to 75 underlying conditions.
Part 1. Today, drugs used to treat NP drugs include more than 60 agents across 20 drug classes. Many of these drugs, such as the anticonvulsants and antidepressants, were developed for other indications, but have utility in the treatment of NP, albeit it in increasingly complex combinations. Part 1 of this report presents a comprehensive update on emerging drug candidates for NP. The current development pipeline shows just 11 Phase III candidates, three of which are based on new or novel drug targeting mechanisms for NP. Phase II however shows a very different picture, with 32 candidates, 20 (63%) of which are based on new or novel mechanisms. Overall, of the 85 pipeline candidates between Phase III and preclinical development, 33 (39%) represent new or novel mechanisms. The drug pipeline is also showing increasing convergence in the targeting strategies that pharmaceutical companies are developing, to combat NP.
Part 2 of this report presents the findings of a global survey on current therapeutic approaches to the treatment of Neuropathic Pain (NP). These findings were made following the participation of more than 350 physicians, who provided details of their treatments and prescribing practices. NP is highly individual in its presentation, level, underlying pathology and response to therapy. For some patients, available therapies give satisfactory pain control. For many others, treatments are poor or do not work at all. Therapeutic options include up to 20 drug classes, which are commonly prescribed in combinations tailored to individual patient needs. Interventional treatments, such as peripheral nerve block and transcutaneous electrical nerve stimulation, are also used as physicians seek other approaches to treating NP. This background, the individual nature of NP and the drug (or drug combination) options used to treat patients, has created a complex therapeutic picture.
In a therapeutic field where treatments are often unsatisfactory, physicians seek to extent their understanding of NP in an effort to define needs and limitations. Knowledge in these areas is also important to drug developers, who seek a better understanding of patient needs and outcomes as part of their own efforts to develop more effective therapies. To meet interest in these areas, Biopharm Reports has conducted an in-depth global survey on current treatments and drug prescribing practices, relating to NP. This survey involved the participation of more than 350 physicians and clinical centres in 56 countries. As part of this study, pain physicians were asked to described current limitations relating to the treatment of neuropathic pain. This report presents an an analysis of these findings.
The report includes:
1) Comprehensive details of current treatments for NP, provided by more than 330 clinics in 56 countries
2) In-depth information relevant to markets and opportunities in the NP field
3) 98% of participants are practicing physicians, working in specialised areas of pain treatment. Of these, 78% described themselves as specialists in pain treatment
4) Leading participant countries were USA, Canada, UK, Australia, Denmark, France, Brazil, Germany, Netherlands and Belgium
5) 74% of the clinical centres participating in this study were hospital pain departments, specialised pain practices or private pain clinics. Detailed information on the use of specific drug classes including tricyclic antidepressants, SSRIs, SNRIs, anticonvulsants, sodium channel blockers, opioids, NSAIDS, cannabinoids and Capsaicin
6) Physicians have provided detailed feedback on the underlying pathologies associated with NP, seen in their patients
7) Comprehensive information on the most frequently prescribed drugs from nine drugs classes, including drug combinations, for the treatment of NP. Biopharm Reports believes this provides the most comprehensive and up-to-date review and analysis in this area currently available
8) A detailed analysis of interventional methods used for the treatment of NP (e.g. peripheral nerve block, TENS)
9) An assessment of average levels of pain relief achieved in the treatment of NP, in relation to 12 underlying conditions
10) Informative views of participating physicians on current limitations, challenges and issues relating to the treatment of NP
Customers who bought this item also bought
Neuropathic Pain: Competing Treatments and Market Entry Considerations
Neuropathic Pain: Treatments and Prescribing Practices - A Global Survey 2009
Neuropathic Pain: A Global Survey of Treatment Practices
The Global Pain Therapeutics Market, 4th Edition: Market Trends & R&D Insights
Pain Therapeutics - Drugs, Markets and Companies
Peripheral Neuropathy and Neuropathic Pain 2008
US Cancer Pain Report
US Neuropathic Pain 2008 - 4th Edition: Market Potential Through 2018
Back Pain Report 2008
Alzheimer's Disease: Competing Treatments and Market Entry Considerations
|
|
|
|
